Special Issue

Imaging Biomarkers for Retinal Diseases: Prognostic Tools and Novel Clinical Trial Endpoints for Precision Medicine

Message from the Guest Editor

Advancements in imaging technology have transformed the field of retinal diseases through new insights in disease pathogenesis and prognosis. Advancements in image feature extraction and analysis technology, such as machine learning, has enabled the next-generation identification and quantification of imaging biomarkers for macular diseases across multiple imaging modalities. These biomarkers present unique opportunities to enhance personalized medicine in retinal disease management through improved patient education, progression risk prognostication, clinical trial enrichment, and even new potential end points. As new therapies emerge, the enhanced phenotyping of these biomarkers may provide important information regarding precision medicine and decision-making for treatment. This Special Issue of the Journal for Personalized Medicine aims to highlight imaging biomarkers for retinal diseases across various modalities using advanced image analysis techniques. We look forward to receiving manuscripts related to new imaging biomarker discovery, image analysis techniques, and assessments of imaging biomarkers within clinical trial datasets.

Guest Editor

Prof. Dr. Justis P. Ehlers

Tony and Leona Campane Center for Excellence in Image-Guided Surgery and Advanced Imaging Research, Cole Eye Institute, Cleveland Clinic, OH, USA

Deadline for manuscript submissions

closed (31 May 2024)

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/si/159713

Journal of Personalized Medicine
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

mdpi.com/journal/jpm

Journal of Personalized Medicine

an Open Access Journal by MDPI

CiteScore 6.0
Indexed in PubMed

mdpi.com/journal/jpm

About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine is one of the few journals that covers the diverse areas involved in the field, including research at basic, translational, and clinical levels. It focuses on "omics"-level studies that seek to define the basis of interindividual variation in susceptibility for a disease, its prognosis or definition of clinical
subsets, and response to therapy (pharmacogenomics). We are also interested in systems biology as it relates to interindividual variation, and research on new methodologies, informatics, and biostatistics, in the aforementioned areas.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker
Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W.F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).

MDPI